How promiscuous are pharmaceutically relevant compounds? A data-driven assessment

AAPS Journal

Volumn 15, Issue 1, 2013, Pages 104-111

  Hu, Ye ^a   Bajorath, Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

activity data; compound promiscuity; database mining; pharmaceutically relevant compounds; polypharmacology; target families; target proteins

Indexed keywords

CHEMICAL COMPOUND;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; DATA MINING; DECOMPOSITION; EQUILIBRIUM CONSTANT; MOLECULAR WEIGHT;

DRUG DISCOVERY; HUMANS;

EID: 84872002166     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9421-y     Document Type: Article

References (24)

1. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol. 2006;24(7):805-15. doi: 10.1038/nbt1228. (Pubitemid 44086621)
2. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197-206. doi: 10.1038/nbt1284. (Pubitemid 46227119)
3. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90. doi: 10.1038/nchembio.118.
4. Keiser MJ, Setola V, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175-81. doi: 10.1038/nature08506.
5. Mestres J, Gregori-Puigjané E. Conciliating binding efficiency and polypharmacology. Trends Pharmacol Sci. 2009;30(9):470-4. doi: 10.1016/j.tips.2009.07.004.
6. Merino A, Bronowska AK, Jackson DB, Cahill DJ. Drug profiling: knowing where it hits. Drug Discov Today. 2010;15(17-18):749-56. doi: 10.1016/j.drudis.2010.06.006.
7. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. Data completeness - the Achilles heel of drug-target networks. Nat Biotechnol. 2008;26(9):983-4. doi: 10.1038/nbt0908-983.
8. Koutsoukas A, Simms B, Kirchmair J, Bond PJ, Whitmore AV, Zimmer S, Young MP, Jenkins JL, Glick M, Glen RC, Bender A. From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteomics. 2011;74(12):2554-74. doi: 10.1016/j.jprot.2011.05.011.
9. Xie L, Xie L, Kinnings SL, Bourne PE. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol. 2012;52:361-79. doi: 10.1146/annurev-pharmtox-010611-134630.
10. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-83. doi: 10.1038/nrd1468. (Pubitemid 39173508)
11. Chong CR, Sullivan DJ. New uses for old drugs. Nature. 2007;448(7154):645-6. doi: 10.1038/448645a. (Pubitemid 47236844)
12. Hu Y, Bajorath J. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs. J Chem Inf Model. 2010;50(12):2112-8. doi: 10.1021/ci1003637.
13. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem. 2007;2(6):861-73. doi: 10.1002/cmdc.200700026.
14. Brown JB, Okuno Y. Systems biology and systems chemistry: new directions for drug discovery. Chem Biol. 2012;19(1):23-8. doi: 10.1016/j.chembiol.2011.12. 012.
15. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012;40(D1):D1100-7. doi: 10.1093/nar/gkr777.
16. UniProtConsortium. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res. 2012;40(D1):D142-8. doi: 10.1093/nar/gkr981.
17. Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. J Med Chem. 1996;39(15):2887-93. doi: 10.1021/jm9602928. (Pubitemid 26251026)
18. Molecular Operating Environment (MOE), 2011.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2011.
19. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011;39(Database issue):D1035-41. doi: 10.1093/nar/gkq1126.
20. Hu Y, Bajorath J. Many structurally related drugs bind different targets whereas distinct drugs display significant target overlap. RSC Adv. 2012;2(8):3481-9. doi: 10.1039/C2RA01345B.
21. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol. 2006;16(1):127-36. doi: 10.1016/j.sbi.2006.01. 013. (Pubitemid 43221881)
22. Fabian MA, Biggs III WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-36. doi: 10.1038/nbt1068. (Pubitemid 41094421)
23. Sturm N, Desaphy J, Quinn RJ, Rognan D, Kellenberger E. Structural insights into the molecular basis of the ligand promiscuity. J Chem Inf Model. 2012;52(9):2410-21. doi: 10.1021/ci300196g.
24. Evans BE, Rittle KE, Bock MG, Dipardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988;31(12):2235-46. doi: 10.1021/jm00120a002. (Pubitemid 19001640)